8-K/A: Shuttle Pharmaceuticals Amends Merger Filing, No Financials Required

Shuttle Pharmaceuticals Holdings, Inc. has amended a prior 8-K filing to clarify that its recent merger transaction does not qualify as a business combination, thus negating the need for UDC's financial statements.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. (the Company) filed an amendment (Form 8-K/A) to its original Form 8-K filed on May 7, 2026.
• The amendment clarifies that the previously announced merger with United Dogecoin Inc. (UDC) is not accounted for as a business combination under ASC 805.
• This determination was made after management, in consultation with financial advisors, concluded that UDC did not meet the definition of a business at the time of the merger closing.
• UDC was in the development stage with no revenue, material assets, mining rigs, or organized workforce.
• Consequently, the historical financial statements of UDC and pro forma financial information are not required to be filed.
• The original filing's disclosure of the merger under Item 2.01 of Form 8-K is amended to reflect that the transactions are not significant and the financial information is not applicable.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative score due to the company amending a previous filing to state that a significant transaction is not a business combination and therefore financial statements are not required, indicating a potential misstatement or lack of clarity in initial reporting.

Positives

• Clarification of accounting treatment for the merger, providing a more accurate financial reporting picture.
• Avoidance of potentially complex and burdensome financial statement filings for UDC, which had no revenue-generating operations.

Negatives

• The amendment suggests a potential misinterpretation or misstatement in the original 8-K filing regarding the significance and nature of the merger.
• The lack of required financial statements for UDC indicates it was an early-stage entity with no established financial track record.

Risks

• Potential for investor confusion or concern regarding the initial reporting of the merger and the subsequent amendment.
• The nature of UDC as a development-stage entity with no revenue raises questions about the strategic value or substance of the merger for Shuttle Pharmaceuticals.

Future Outlook

No specific forward-looking statements or guidance were provided in this amendment, which solely addresses the accounting treatment of a past event.

Management Comments

• Management, in consultation with financial advisors, determined that UDC does not meet the definition of a business under ASC 805.
• The merger would not be accounted for as a business combination under ASC 805.
• Control over UDC's operations remained with its Board of Directors until stockholder approval of share issuance.
• UDC had no material assets to which estimated transaction costs could be allocated.
• The reverse acquisition model is not applicable as UDC did not obtain control of the Company.
• Historical and pro forma financial statements are not required as UDC does not meet the definition of a business.

Industry Context

StockSavvy.ai notes that the clarification of business combination accounting is crucial for accurate financial reporting. Companies must carefully assess whether an acquired entity meets the definition of a business under ASC 805 to determine the appropriate accounting treatment, which can significantly impact reported financials.

Stakeholder Impact

• Shareholders may have concerns about the initial reporting of the merger and the subsequent clarification, potentially impacting confidence in management's disclosures.
• Investors will need to understand that the reported transaction does not represent a business acquisition in the traditional sense, as UDC was a development-stage entity.

Next Steps

• The Company has amended its original Form 8-K to reflect the correct accounting treatment for the merger with UDC.
• No further financial statements or pro forma information related to UDC are required to be filed.

Key Dates

Keywords

Merger, Business Combination, ASC 805, Financial Statements, Amendment, SEC Filing, Development Stage, Regulation S-X